The research showed that miRNA-146a could relieve colitis and CRC by targeting TRAF6, PTGES2, and TLR4/MyD88/NF-κB signaling pathways (Wang et al., 2019; Garo et al., 2021). The gene discussed is NFKB1; the disease is colorectal carcinoma.